Investors should monitor upcoming FDA discussions and NDA submission timing. The durability and rescue-free rates support strong commercial potential, especially given high treatment burden in current wet AMD therapies. Approval could lead to rapid adoption and market share gains.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $8.86entry
- T+1 · 7mo ago −1.13%α −2.34% · $8.76
- T+5 · 7mo ago +7.45%α +4.15% · $9.52
- T+20 · 6mo ago +4.74%α −2.99% · $9.28
- T+60 · 4mo ago +15.91%α +6.99% · $10.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix presented additional Week 52 post-hoc data from its SOL-1 Phase 3 trial for AXPAXLI, an investigational therapy for wet AMD, demonstrating superior durability and sustained disease control compared to aflibercept. The company remains on track to submit an NDA based on SOL-1 alone, pending formal discussions with the FDA, aligning with recent FDA commentary supporting single-trial approval pathways.
Key Facts
- AXPAXLI showed a median time to ≥30 μM CSFT increase of 39 weeks vs. 16 weeks for aflibercept, a 23-week difference (hazard ratio 0.7, p=0.0028).
- Median time to ≥75 μM CSFT increase was 46 weeks for AXPAXLI vs. 24 weeks for aflibercept (hazard ratio 0.5, p<0.0001).
- 81% of AXPAXLI subjects were rescue-free at Week 24; 75% remained rescue-free at Week 36.
- Visual acuity gains from the loading phase were maintained through Week 52 across BCVA quartiles.
- No significant safety events such as endophthalmitis or vasculitis; vitreous floaters resolved with mean clearance time of 20 weeks.
- Company plans NDA submission based on SOL-1 alone, consistent with FDA's anticipated shift toward single pivotal trial approvals.
Financial Impact
Potential blockbuster approval in a $1.9B market; could significantly expand OCUL's revenue base if approved.
Risk Factors
- FDA may not accept NDA based on a single pivotal trial despite recent commentary.
- Long-term safety or efficacy could diverge in later trial phases or real-world use.
- Commercial execution risk upon launch, including payer reimbursement and physician adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272358 |
Track record
20 reports on OCUL
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers